Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25619797 | 0.91 | ALDH1A1 (0.52) | POLBALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25619364 | 0.86 | ALDH1A1 (0.54) | POLBALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25620124 | 0.86 | POLB (0.47) | POLBALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25617671 | 0.86 | ALDH1A1 (0.56) | POLBALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25621288 | 0.83 | POLB (0.51) | POLBALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25619845 | 0.83 | POLB (0.43) | POLBALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25620087 | 0.82 | ALDH1A1 (0.50) | POLBALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25617808 | 0.82 | ALDH1A1 (0.48) | POLBALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25617668 | 0.79 | ALDH1A1 (0.52) | POLBALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25619108 | 0.79 | ALDH1A1 (0.56) | POLBALDH1A1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661404-B2 | Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders | ACHILLES MEDICAL LIMITED (NZ) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661404-B2 | Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders | AKR1C2, AKR1C1, AKR1B1 | POLB 1186/4885ALDH1A1 61/4885CYP3A4 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.